ORCID Profile
0000-0002-4911-8507
Current Organisation
National University Singapore Yong Loo Lin School of Medicine
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 14-12-2020
DOI: 10.1111/JCH.14128
Publisher: Wiley
Date: 04-01-2022
DOI: 10.1111/JCH.14336
Abstract: Cardiovascular disease (CVD) is becoming the most important burden to health care systems in most part of the world, especially in Asia. Aiming at identifying high risk in iduals and tailoring preventive treatment, many cardiovascular risk assessment tools have been established and most of them were developed in Western countries. However, these cardiovascular risk assessment tools cannot be used interchangeably without recalibration because of the different risk factor profiles (ie, greater absolute burden of hypertension and lower level of total‐cholesterol in Asians and higher prevalence of metabolic disorders in South Asians) and different CVD profiles (higher ratio of stroke/coronary heart disease in Asians) between Western and Asian populations. Original risk models such as Prediction for ASCVD Risk in China (China‐PAR) and Japan Arteriosclerosis Longitudinal Study (JALS) score have been developed and well validated for specific countries, while most of countries/regions in Asia are using established models. Due to higher incidence of stroke in Asians, risk factors like hypertension should weigh more in cardiovascular risk assessment comparing with Western populations, but their actual proportions should be based on CVD profiles in specific countries/regions. The authors encourage the development of new cardiovascular risk assessment tools for Asians, if possible. Still, modifying established models with native epidemiological data of risk factor as well as CVD is acceptable in regions where health care resources are insufficient.
Publisher: Wiley
Date: 03-12-2020
DOI: 10.1111/JCH.14116
Publisher: Wiley
Date: 09-2022
DOI: 10.1111/JCH.14555
Abstract: Morning hypertension is an important clinical target in the management of hypertension for perfect 24‐h blood pressure (BP) control. Morning hypertension is generally categorized into two types: “morning surge” type and “sustained nocturnal and morning hypertension” type. The “morning surge” type is characterized by an exaggerated morning blood pressure surge (MBPS), and the “sustained nocturnal and morning hypertension” type with continuous hypertension from nighttime to morning (non‐dipper/riser type). They can be detected by home and ambulatory blood pressure measurements (HBPM and ABPM). These two forms of morning hypertension both increase the risk of cardiovascular and renal diseases, but may occur via different pathogenic mechanisms and are associated with different conditions. Morning hypertension should be treated to achieve a morning BP level of 135/85 mmHg, regardless of the office BP. The second target morning BP levels is 125/75 mmHg for high‐risk patients with morning hypertension and concomitant diseases. Morning hypertension is more frequently found in Asians, than in Westerners. Thus, the management of morning hypertension is especially important in Asia. The detection of morning hypertension and the in idual home BP‐guided treatment approach targeting morning BP in combination with ABPM, and the optimal treatment of morning hypertension would reduce cardiovascular events in Asia.
Publisher: Wiley
Date: 14-12-2020
DOI: 10.1111/JCH.14123
Publisher: Wiley
Date: 16-12-2019
DOI: 10.1111/JCH.13758
Publisher: JMIR Publications Inc.
Date: 21-09-2016
DOI: 10.2196/RESPROT.6282
Publisher: Informa UK Limited
Date: 07-2017
DOI: 10.2147/VHRM.S138694
Publisher: Informa UK Limited
Date: 07-2017
DOI: 10.2147/IJGM.S138789
Publisher: Wiley
Date: 11-12-2020
DOI: 10.1111/JCH.14120
Publisher: Wiley
Date: 30-12-2020
DOI: 10.1111/JCH.14163
Publisher: Wiley
Date: 04-02-2021
DOI: 10.1111/JCH.14188
Publisher: Wiley
Date: 07-12-2020
DOI: 10.1111/JCH.14121
Publisher: Wiley
Date: 02-2021
DOI: 10.1111/JCH.14192
Publisher: Wiley
Date: 19-12-2020
DOI: 10.1111/JCH.14140
Location: Singapore
No related grants have been discovered for Boon Wee Teo.